DE69918691D1 - Glucagonähnliches peptid 1 (glp-1) verbessert die beta zellen antwort auf glukose in patienten mit verminderter glukosetoleranz - Google Patents

Glucagonähnliches peptid 1 (glp-1) verbessert die beta zellen antwort auf glukose in patienten mit verminderter glukosetoleranz

Info

Publication number: DE69918691D1
Authority: DE; Germany
Prior art keywords: glucosetolerance; glp; glucagon; peptide; glucose
Prior art date: 1998-06-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Revoked

Application number

DE69918691T

Other languages

English (en)

Other versions

DE69918691T2 (de

Inventor

Burkhard Goke

Maria Byrne

R Thomas

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Amylin Pharmaceuticals LLC

Original Assignee

Amylin Pharmaceuticals LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-12

Filing date

1999-05-07

Publication date

2004-08-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22215287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69918691(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-05-07 Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC

2004-08-19 Publication of DE69918691D1 publication Critical patent/DE69918691D1/de

2005-07-21 Application granted granted Critical

2005-07-21 Publication of DE69918691T2 publication Critical patent/DE69918691T2/de

2019-05-08 Anticipated expiration legal-status Critical

Status Revoked legal-status Critical Current

Links

WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title 1
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 title 1
230000036755 cellular response Effects 0.000 title 1
239000008103 glucose Substances 0.000 title 1
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Endocrinology (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DE69918691T 1998-06-12 1999-05-07 Glucagonähnliches peptid 1 (glp-1) verbessert die beta zellen antwort auf glukose in patienten mit verminderter glukosetoleranz Revoked DE69918691T2 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US8904498P	1998-06-12	1998-06-12
US89044P		1998-06-12
PCT/US1999/010040 WO1999064061A1 (en)	1998-06-12	1999-05-07	GLUCAGON-LIKE PEPTIDE-1 IMPROVES β-CELL RESPONSE TO GLUCOSE IN SUBJECTS WITH IMPAIRED GLUCOSE TOLERANCE

Publications (2)

Publication Number	Publication Date
DE69918691D1 true DE69918691D1 (de)	2004-08-19
DE69918691T2 DE69918691T2 (de)	2005-07-21

Family

ID=22215287

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69918691T Revoked DE69918691T2 (de)	1998-06-12	1999-05-07	Glucagonähnliches peptid 1 (glp-1) verbessert die beta zellen antwort auf glukose in patienten mit verminderter glukosetoleranz

Country Status (30)

Country	Link
US (1)	US7265087B1 (de)
EP (2)	EP1083924B1 (de)
JP (1)	JP2002517469A (de)
KR (1)	KR20010052800A (de)
CN (1)	CN1209166C (de)
AP (1)	AP2001002027A0 (de)
AT (1)	ATE270897T1 (de)
AU (2)	AU758825B2 (de)
BG (1)	BG64975B1 (de)
BR (1)	BR9911112A (de)
CA (1)	CA2334872C (de)
CZ (1)	CZ294848B6 (de)
DE (1)	DE69918691T2 (de)
DK (1)	DK1083924T3 (de)
EA (1)	EA004538B1 (de)
ES (1)	ES2224659T3 (de)
GE (1)	GEP20033015B (de)
HU (1)	HUP0102193A2 (de)
ID (1)	ID28617A (de)
IL (2)	IL140223A0 (de)
MX (1)	MXPA00012286A (de)
NO (1)	NO20006336L (de)
NZ (2)	NZ527473A (de)
OA (1)	OA11694A (de)
PL (1)	PL195662B1 (de)
PT (1)	PT1083924E (de)
SK (1)	SK19042000A3 (de)
TR (1)	TR200100079T2 (de)
UA (1)	UA69412C2 (de)
WO (1)	WO1999064061A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6344180B1 (en)	1999-06-15	2002-02-05	Bionebraska, Inc.	GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
US20020025306A1 (en) *	2000-01-07	2002-02-28	Baetge Edward E.	Methods of increasing the glucose responsiveness of pancreatic ss-cells
CA2405709A1 (en)	2000-04-12	2001-10-25	Human Genome Sciences, Inc.	Albumin fusion proteins
AU2002224124A1 (en)	2000-12-01	2002-06-11	Takeda Chemical Industries Ltd.	Method for producing preparation containing bioactive substance
ES2545090T3 (es)	2001-12-21	2015-09-08	Human Genome Sciences, Inc.	Proteínas de fusión de albúmina y GCSF
WO2005003296A2 (en)	2003-01-22	2005-01-13	Human Genome Sciences, Inc.	Albumin fusion proteins
ES2300568T3 (es)	2002-03-20	2008-06-16	Mannkind Corporation	Aparato de inhalacion.
US7731947B2 (en)	2003-11-17	2010-06-08	Intarcia Therapeutics, Inc.	Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US8921311B2 (en) *	2003-08-01	2014-12-30	Mannkind Corporation	Method for treating hyperglycemia
BRPI0514263B8 (pt)	2004-08-20	2021-05-25	Mannkind Corp	método para a síntese de bis-3,6-[4-aminobutil]-2,5-dicetopiperazina n-protegida
KR101306384B1 (ko)	2004-08-23	2013-09-09	맨카인드 코포레이션	약물 전달용 디케토피페라진염, 디케토모르포린염 또는디케토디옥산염
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en)	2005-02-03	2006-08-10	Alza Corporation	Solvent/polymer solutions as suspension vehicles
US8052996B2 (en)	2005-02-03	2011-11-08	Intarcia Therapeutics, Inc.	Two-piece, internal-channel osmotic delivery system flow modulator
RU2007149288A (ru) *	2005-05-27	2009-07-10	Асубио Фарма Ко., Лтд. (Jp)	Средство для снижения устойчивости к инсулину
MX381952B (es)	2005-09-14	2025-03-13	Mannkind Corp	Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
JP5599975B2 (ja)	2006-02-22	2014-10-01	マンカインドコーポレイション	ジケトピペラジン及び活性薬剤を含有する微粒子の製剤特性の改善方法
EP2574624A1 (de)	2006-04-20	2013-04-03	Amgen Inc.	GLP-1-Verbindungen
PT2359808E (pt)	2006-08-09	2013-08-28	Intarcia Therapeutics Inc	Sistemas de entrega osmótica e montagens de pistão
RU2413528C2 (ru)	2007-01-18	2011-03-10	Открытое Акционерное Общество "Валента Фармацевтика"	Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
PL2157967T3 (pl)	2007-04-23	2013-06-28	Intarcia Therapeutics Inc	Formulacje zawiesinowe peptydów insulinotropowych i ich zastosowania
WO2009033711A2 (en) *	2007-09-11	2009-03-19	Mondobiotech Laboratories Ag	Use of a peptide as a therapeutic agent
WO2009039963A1 (en) *	2007-09-11	2009-04-02	Mondobiotech Laboratories Ag	Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent
WO2011163272A1 (en)	2010-06-21	2011-12-29	Mannkind Corporation	Dry powder drug delivery system and methods
CA2726861C (en)	2008-02-13	2014-05-27	Intarcia Therapeutics, Inc.	Devices, formulations, and methods for delivery of multiple beneficial agents
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
KR101762089B1 (ko)	2008-06-13	2017-07-26	맨카인드 코포레이션	건조 분말 흡입기 및 약물 투여 시스템
ES2421385T3 (es)	2008-06-20	2013-09-02	Mannkind Corp	Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
US20120058105A1 (en) *	2008-06-27	2012-03-08	Martin Kean Chong Ng	Method of treatment of vascular complications
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
HUE035862T2 (en)	2009-09-28	2018-05-28	Intarcia Therapeutics Inc	Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
ES2625858T3 (es)	2011-04-01	2017-07-20	Mannkind Corporation	Paquete de tipo blíster para cartuchos farmacéuticos
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
CN103945859A (zh)	2011-10-24	2014-07-23	曼金德公司	用于治疗疼痛的方法和组合物
US20150157619A1 (en)	2012-07-10	2015-06-11	Takeda Pharmaceutical Company Limited	Pharmaceutical preparation for injection
CN108057154B (zh)	2012-07-12	2021-04-16	曼金德公司	干粉药物输送系统和方法
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
EA031428B1 (ru)	2012-12-21	2018-12-28	Санофи	Функционализированные производные эксендина-4
EP3021834A1 (de)	2013-07-18	2016-05-25	MannKind Corporation	Hitzestabile pharmazeutische trockenpulverzusammensetzungen und verfahren
EP3030294B1 (de)	2013-08-05	2020-10-07	MannKind Corporation	Insufflationsvorrichtung
TW201609797A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／升糖素受體促效劑
EP3080150B1 (de)	2013-12-13	2018-08-01	Sanofi	Exendin-4-peptidanaloga als duale glp-1/gip-rezeptoragonisten
TW201609799A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／ｇｉｐ受體促效劑
EP3080152A1 (de)	2013-12-13	2016-10-19	Sanofi	Nicht-acylierte exendin-4-peptidanaloga
WO2015148905A1 (en)	2014-03-28	2015-10-01	Mannkind Corporation	Use of ultrarapid acting insulin
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
RU2573933C1 (ru)	2014-08-21	2016-01-27	Дафот Энтерпрайсис Лимитед	Пептид для лечения сахарного диабета 2-го типа и его осложнений
CN104267194B (zh) *	2014-09-23	2016-01-13	上海市东方医院	人胰高血糖素样肽-1、抗体及其试剂盒
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
MX2017015504A (es)	2015-06-03	2018-05-15	Intarcia Therapeutics Inc	Sistemas de colocacion y remoción de implante.
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CA3024479A1 (en)	2016-05-16	2017-11-23	Intarcia Therapeutics, Inc.	Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
CN110225762A (zh)	2017-01-03	2019-09-10	因塔西亚制药公司	包括glp-1受体激动剂的连续施用和药物的共同施用的方法
US12257287B2 (en)	2018-11-12	2025-03-25	Tianjin Institute Of Pharmaceutical Research Co., Ltd.	Glucagon-derived peptide and use thereof
CN113430154A (zh) *	2021-05-21	2021-09-24	深圳市前海金卓生物技术有限公司	分泌glp-1的蛋白表达系统及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2257119A1 (en)	1996-06-05	1997-12-11	Boehringer Mannheim Gmbh	Exendin analogues, processes for their production and pharmaceutical preparations containing them
US6277819B1 (en)	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
US6344180B1 (en) *	1999-06-15	2002-02-05	Bionebraska, Inc.	GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes

1999
- 1999-05-07 PT PT99921778T patent/PT1083924E/pt unknown
- 1999-05-07 AT AT99921778T patent/ATE270897T1/de not_active IP Right Cessation
- 1999-05-07 DK DK99921778T patent/DK1083924T3/da active
- 1999-05-07 DE DE69918691T patent/DE69918691T2/de not_active Revoked
- 1999-05-07 PL PL99345212A patent/PL195662B1/pl unknown
- 1999-05-07 EP EP99921778A patent/EP1083924B1/de not_active Revoked
- 1999-05-07 CN CNB998091812A patent/CN1209166C/zh not_active Expired - Fee Related
- 1999-05-07 IL IL14022399A patent/IL140223A0/xx unknown
- 1999-05-07 JP JP2000553129A patent/JP2002517469A/ja active Pending
- 1999-05-07 NZ NZ527473A patent/NZ527473A/en not_active IP Right Cessation
- 1999-05-07 US US09/719,410 patent/US7265087B1/en not_active Expired - Fee Related
- 1999-05-07 EP EP04075402A patent/EP1419783A3/de not_active Withdrawn
- 1999-05-07 WO PCT/US1999/010040 patent/WO1999064061A1/en not_active Application Discontinuation
- 1999-05-07 BR BR9911112-8A patent/BR9911112A/pt not_active IP Right Cessation
- 1999-05-07 AP APAP/P/2001/002027A patent/AP2001002027A0/en unknown
- 1999-05-07 ES ES99921778T patent/ES2224659T3/es not_active Expired - Lifetime
- 1999-05-07 MX MXPA00012286A patent/MXPA00012286A/es unknown
- 1999-05-07 CA CA2334872A patent/CA2334872C/en not_active Expired - Fee Related
- 1999-05-07 EA EA200100029A patent/EA004538B1/ru not_active IP Right Cessation
- 1999-05-07 ID IDW20010100A patent/ID28617A/id unknown
- 1999-05-07 NZ NZ508823A patent/NZ508823A/en not_active IP Right Cessation
- 1999-05-07 HU HU0102193A patent/HUP0102193A2/hu unknown
- 1999-05-07 GE GEAP19995661A patent/GEP20033015B/en unknown
- 1999-05-07 TR TR2001/00079T patent/TR200100079T2/xx unknown
- 1999-05-07 OA OA1200000341A patent/OA11694A/en unknown
- 1999-05-07 AU AU38899/99A patent/AU758825B2/en not_active Ceased
- 1999-05-07 CZ CZ20004614A patent/CZ294848B6/cs not_active IP Right Cessation
- 1999-05-07 SK SK1904-2000A patent/SK19042000A3/sk unknown
- 1999-05-07 KR KR1020007014110A patent/KR20010052800A/ko not_active Application Discontinuation
- 1999-07-05 UA UA2000127165A patent/UA69412C2/uk unknown
2000
- 2000-12-11 IL IL140223A patent/IL140223A/en not_active IP Right Cessation
- 2000-12-12 NO NO20006336A patent/NO20006336L/no not_active Application Discontinuation
- 2000-12-21 BG BG105079A patent/BG64975B1/bg unknown
2003
- 2003-07-03 AU AU2003212050A patent/AU2003212050B2/en not_active Ceased

Also Published As

Publication number	Publication date
GEP20033015B (en)	2003-07-25
EA200100029A1 (ru)	2001-10-22
WO1999064061A1 (en)	1999-12-16
ATE270897T1 (de)	2004-07-15
NO20006336L (no)	2001-02-12
PT1083924E (pt)	2004-10-29
NO20006336D0 (no)	2000-12-12
EP1083924A1 (de)	2001-03-21
JP2002517469A (ja)	2002-06-18
BG105079A (en)	2001-09-28
AU2003212050B2 (en)	2006-02-16
OA11694A (en)	2005-01-12
US7265087B1 (en)	2007-09-04
UA69412C2 (uk)	2004-09-15
CA2334872C (en)	2014-08-19
ID28617A (id)	2001-06-21
EA004538B1 (ru)	2004-06-24
CN1209166C (zh)	2005-07-06
TR200100079T2 (tr)	2001-06-21
CZ294848B6 (cs)	2005-03-16
SK19042000A3 (sk)	2001-11-06
KR20010052800A (ko)	2001-06-25
CA2334872A1 (en)	1999-12-16
BG64975B1 (bg)	2006-11-30
AU3889999A (en)	1999-12-30
AU2003212050A1 (en)	2003-08-14
HUP0102193A2 (hu)	2001-10-28
PL195662B1 (pl)	2007-10-31
BR9911112A (pt)	2001-11-27
CN1311687A (zh)	2001-09-05
NZ508823A (en)	2003-10-31
EP1083924B1 (de)	2004-07-14
AU758825B2 (en)	2003-04-03
IL140223A0 (en)	2002-02-10
AP2001002027A0 (en)	2001-03-31
MXPA00012286A (es)	2002-10-17
EP1419783A3 (de)	2005-01-12
IL140223A (en)	2010-12-30
PL345212A1 (en)	2001-12-03
CZ20004614A3 (en)	2001-06-13
NZ527473A (en)	2005-02-25
ES2224659T3 (es)	2005-03-01
EP1419783A2 (de)	2004-05-19
DK1083924T3 (da)	2004-11-22
DE69918691T2 (de)	2005-07-21

Publication	Publication Date	Title
DE69918691D1 (de)	2004-08-19	Glucagonähnliches peptid 1 (glp-1) verbessert die beta zellen antwort auf glukose in patienten mit verminderter glukosetoleranz
TR200100600T2 (tr)	2001-07-23	İnsülinotropik peptitlerin kullanımı.
DE69131250D1 (de)	1999-06-24	Rohrelement aus verbundwerkstoff mit mehreren zellen
EE05210B1 (et)	2009-10-15	Suhkurt?vevastane preparaat ja selle kasutamine meditsiinis
ID22053A (id)	1999-08-26	Turunan asam aminofosfonat dalam sediaan farmasi
PT1017408E (pt)	2005-07-29	Utilizacao de tetra-hidrolipstatina no tratamento de diabetes de tipo ii
IT1291366B1 (it)	1999-01-07	Composizione farmaceutica antivirale comprendente acido glicirrizico ed almeno una proteina dotata di attivita' antivirale
EP0985732A3 (de)	2003-10-01	Trimerisches chimäres Protein und Kollagenmatrix enthaltend chimäres Protein
AU4557001A (en)	2001-09-24	Induction of beta cell differentiation in human cells by stimulation of the glp-1 receptor
IT1235690B (it)	1992-09-21	Procedimento di fabbricazione per una matrice di celle eprom organizzate a tovaglia.
DK0759775T3 (da)	2000-11-13	Flydende IFN-beta-formuleringer
NO981377D0 (no)	1998-03-26	Fremstilling av en supraledende flerleder i sölvbasismatrise
ATE252909T1 (de)	2003-11-15	Pharmazeutische zubereitung enthaltend peptide mit geringer löslichkeit in physiologischem medium
IL112967A0 (en)	1995-06-29	Pharmaceutical compositions comprising a complex carbohydrate to diminish hypoglycemia in patients with diabetes mellitus
BRPI0506694A (pt)	2007-05-02	análogos de peptìdeo-1 semelhante ao glucagon com longa duração de ação
ATE277948T1 (de)	2004-10-15	Bpc peptid salze mit organ-schützender aktivität, deren herstellung und therapeutische verwendung
CA2296178A1 (en)	2000-08-09	Human intestinal npt2b
IT1241123B (it)	1993-12-29	Cellule umane per l'elevata espressione di geni inseriti in dna ricombinanti episomiali,loro preparazione e loro impiego
DE69523239D1 (de)	2001-11-22	Flash eprom-matrix mit virtueller erdung mit reduziertem zellenschrittabstand in der x-richtung
NO20023015D0 (no)	2002-06-21	Humant heparanasebeslektet polypeptid og nukleinsyre
EP0444638A3 (en)	1992-01-08	Process for the expression of human nerve growth factor in arthropoda frugiperda cells by infection with recombinant baculovirus
PL351499A1 (en)	2003-04-22	Expression of heparin-binding protein in recombinant mammalian cells
FR2780639B1 (fr)	2000-11-10	Lit de soins a elements telescopiques en forme de tiges
NO975554D0 (no)	1997-12-02	Oral toleranse i hudsykdommer tilstede med T-celle mediert inflammasjon
ENOKIJIMA et al.	1984	Effect of knobed gene (K) on amount of food ingested, amount of food digested, cocoon weight and cocoon-shell weight in the silkworm, Bombyx mori, reared on artificial diet

Legal Events

Date	Code	Title	Description
2005-07-07	8363	Opposition against the patent
2006-06-08	8331	Complete revocation